Clinical Trial

Diabetes Discharge Transitional CGM Study (DDT-CGM)

Study acronym: DDT-CGM
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2024 (before its estimated July 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Intervention group will receive brief diabetic education, CGM education and use and have a CGM placed before discharge. They will also sign up for "Cloud" access of their CGM data. A medical assistant will review their CGM data daily to make sure they are using the CGM adequately. The principal investigator will review the CGM data and call the patient for a brief phone evaluation of their glucoses and their transition from the hospital to outpatient care. The will be called 4 times between discharge and day 15 by the principal investigator. Standard treatment group will receive a blinded CGM to be reviewed 30 days after discharge. Reduction in hospitalizations and ER visits within the first 30 days is the primary outcome. Time in range, hypoglycemia, hyperglycemia and patient satisfaction will also be evaluated 30 days after discharge.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-01-25; most recent amendment 2025-09-09.
Status change: Active, Not Recruiting → Terminated 2025-09-09
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-02-23
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-09-09
Trial Details
NCT Number NCT04729985
Lead Sponsor Intermountain Health Care, Inc.
Collaborators: Abbott
Conditions Diabetes Mellitus, Type 2
Enrollment 120 participants
Start Date 2021-06-01
Primary Completion 2024-07-01 (estimated)
Study Completion 2024-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-26